The strong beat and guidance raise confirm accelerating royalty momentum, while the XOMA close and $700M deployable capital signal a larger, more diversified platform. Monitor Q3 for initial XOMA contribution and any further royalty acquisitions; the $524.34 warrant strike caps near-term dilution risk.
Price Chart
Executive Summary
Ligand reported Q2 2026 adjusted EPS of $2.37, a 20.3% beat vs consensus of $1.97, driven by 32% YoY royalty revenue growth to $48.0M. The company raised the low end of its 2026 adjusted EPS guidance to $9.00-$9.50 (from $8.50-$9.50) and closed the XOMA Royalty acquisition on July 14, 2026, adding over 120 assets. The strong beat, guidance raise, and transformative acquisition close are clearly positive, but the $700M convertible debt issuance and share repurchase at ~$262 introduce modest dilution and capital structure complexity.
Key Financial Metrics
Key Facts
- Q2 2026 adjusted EPS of $2.37 beat consensus of $1.97 by 20.3%
- Q2 2026 total revenue of $63.7M beat consensus of $61.3M by 3.9%
- Royalty revenue grew 32% YoY to $48.0M, driven by Filspari, Zelsuvmi, and Ohtuvayre
- Raised low end of 2026 adjusted EPS guidance to $9.00-$9.50 (from $8.50-$9.50); revenue guidance unchanged at $270M-$310M
- Closed XOMA Royalty acquisition on July 14, 2026, adding >120 assets for $39.00/share plus CVR
- Completed $700M 0.00% convertible note offering due 2031; used ~$60M to repurchase 228,859 shares at ~$262/share
- Cash, cash equivalents, and short-term investments were $1.36B at June 30, 2026, up from $733.5M at Dec 31, 2025
- Filspari (Travere) Q2 net sales grew 96% YoY to $141M, driven by FSGS launch and IgAN growth
Financial Impact
Adjusted EPS beat consensus by $0.40 (20.3%); revenue beat by $2.4M (3.9%); guidance raised by $0.50 at low end
Risk Factors
- Integration risk from XOMA acquisition; potential for higher-than-expected operating costs
- Dependence on partner commercial execution (Filspari, Ohtuvayre, Capvaxive) for royalty growth
- Convertible debt ($1.13B net) increases leverage; dilution risk if stock exceeds $524.34
- Captisol sales declining (down 4% YoY in Q2) and subject to customer order timing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000886163-26-000041 |
| Document: lgnd-20260806.htm | 0000886163-26-000041 |
| Document: 0000886163-26-000041-index-headers.html | 0000886163-26-000041 |
| Document: 0000886163-26-000041-index.html | 0000886163-26-000041 |
| Document: 0000886163-26-000041.txt | 0000886163-26-000041 |
| 8-K Data (Synthetic) | 0000886163-26-000041 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 17d ago | Insider Cluster | $276.98 $298.50 | ▲ +7.77% | ▲ +5.66% | $302.96 (+9.38%) |
Aug 14, 2026 6w ago | Insider Cluster | $291.77 $280.18 | ▼ −3.97% | ▼ −2.78% | $302.96 (+3.84%) |
Aug 6, 2026 8w ago | 8-K | $300.14 $288.82 | ▼ −3.77% | ▼ −4.98% | $302.96 (+0.94%) |
Jun 25, 2026 14w ago | 8-K | $303.59 $319.55 | ▲ +5.26% | ▲ +3.09% | $302.96 (−0.21%) |
Jun 18, 2026 15w ago | Insider Cluster | $274.88 $295.92 | ▲ +7.65% | ▲ +9.32% | $302.96 (+10.22%) |
Jun 16, 2026 15w ago | Insider Cluster | $255.25 $279.44 | ▲ +9.48% | ▲ +11.71% | $302.96 (+18.69%) |
Jun 12, 2026 15w ago | Insider Cluster | $253.25 $262.17 | ▲ +3.52% | ▲ +4.91% | $302.96 (+19.63%) |
May 1, 2026 22w ago | Insider Cluster | $227.44 $221.41 | ▼ −2.65% | ▼ −5.00% | $302.96 (+33.20%) |
Apr 14, 2026 24w ago | Press Release | $232.34 $226.67 | ▼ −2.44% | ▼ −3.83% | $302.96 (+30.40%) |
Feb 26, 2026 31w ago | 8-K | $196.17 $206.27 | ▲ +5.15% | ▲ +6.28% | $302.96 (+54.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access